Navigation Links
Medarex Announces Completion of Sale of Shares in Genmab A/S
Date:2/1/2008

PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it has completed the sale of approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 1, 2008. Medarex expects to receive approximately $151.8 million (USD) in net proceeds from the sale. The sale of Genmab shares reduces Medarex's ownership in Genmab to approximately 5.1 percent.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
2. Medarex Announces Election of Marc Rubin as New Board Member
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
6. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
7. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
8. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
9. Rigel Announces Pricing of Public Offering of Common Stock
10. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008
11. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... across three states, announced today the promotion of two long-standing principal investigators (PI) ... of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will ... conference in San Francisco’s Moscone Center from February 16-18, 2016, and at the ... These latest InGaAs PIN diode standard packages feature a TO-46 metal can with active ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... ... in regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells ... physicians from the Philippines, Thailand and Singapore in the latest adipose and bone ...
Breaking Biology Technology:
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
Breaking Biology News(10 mins):